Linked Data API

Show Search Form

Search Results

1140806
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Public Health: Disadvantaged more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on health inequalities. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 280246 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.</p><p>The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.</p> more like this
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN 280247 more like this
star this property question first answered
less than 2019-07-25T16:09:54.417Zmore like thismore than 2019-07-25T16:09:54.417Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4131
unstar this property label Biography information for Jim Shannon more like this
1140807
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Public Health: Disadvantaged more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of reductions in public health funding on the health and wellbeing of the most marginalised people in the UK. more like this
star this property tabling member constituency Strangford more like this
star this property tabling member printed
Jim Shannon more like this
star this property uin 280247 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Public health services can have a significant impact in improving the health of the population and reducing unfair differences between marginalised groups of people or communities.</p><p>The Government has made difficult choices to protect public services in the long term. We remain committed to securing five extra years of healthy, independent life by 2035 and reducing the gap between rich and poor with proposals set out in the Prevention Green Paper and a Long Term Plan for the National Health Service with a greater focus on prevention. We want everyone to have the same opportunity to have a long healthy life, whoever they are and whatever their social circumstances.</p> more like this
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN 280246 more like this
star this property question first answered
less than 2019-07-25T16:09:54.467Zmore like thismore than 2019-07-25T16:09:54.467Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4131
unstar this property label Biography information for Jim Shannon more like this
1140868
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Prisoners: Synthetic Cannabinoids more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what programmes there are in prisons to provide support for prisoners with synthetic cannabis drug dependency. more like this
star this property tabling member constituency Mansfield more like this
star this property tabling member printed
Ben Bradley more like this
star this property uin 280382 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>In prison, patients presenting with problematic psychoactive substance use are assessed in the same way as other drug users and offered an appropriate range of psychosocial interventions.</p><p>In April 2018, NHS England and NHS Improvement published its updated service specification on ‘Integrated Substance Misuse Treatment Service in Prisons in England’. This is fully aligned to ‘Drug Misuse and Dependence: UK Guidelines on Clinical Management’, which sets out how clinicians should treat people with drug misuse and drug dependence problems.</p><p>The service specification describes a fully recovery orientated, integrated prison substance misuse treatment service, which covers traditional drugs of abuse, psychoactive substances (including synthetic cannabis), illicit abuse of prescribed and over the counter drugs and alcohol.</p><p>This improved substance misuse service offer is now being commissioned across all prisons and secures integration with mental health services so that growing numbers of people in prisons can access services to support their recovery and wellbeing.</p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:15:47.693Zmore like thismore than 2019-07-25T16:15:47.693Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4663
unstar this property label Biography information for Ben Bradley more like this
1140869
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Mental Health Services: Nottinghamshire more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the (a) availability and (b) waiting times for therapeutic services for mental health conditions in Nottinghamshire. more like this
star this property tabling member constituency Mansfield more like this
star this property tabling member printed
Ben Bradley more like this
star this property uin 280383 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Information on the availability of therapeutic services for mental health conditions delivered through the Improving Access to Psychological Therapies (IAPT) programme in Nottinghamshire clinical commissioning groups (CCGs)<sup>1</sup> is not collected.</p><p>Information on waiting times for such services in the Nottinghamshire CCGs in 2019 is in the following table.</p><table><tbody><tr><td><p>Month</p></td><td><p>Number of referrals finishing a course of treatment</p></td><td><p>Mean wait to enter treatment<sup>2</sup> (days)</p></td><td><p>Percentage of finishing referrals<sup>3</sup> seen within 6 weeks</p></td></tr><tr><td><p>January 2019</p></td><td><p>1,345</p></td><td><p>24.3</p></td><td><p>83</p></td></tr><tr><td><p>February 2019</p></td><td><p>1,290</p></td><td><p>24.8</p></td><td><p>81</p></td></tr><tr><td><p>March 2019</p></td><td><p>1,510</p></td><td><p>25.3</p></td><td><p>79</p></td></tr><tr><td><p>April 2019</p></td><td><p>1,280</p></td><td><p>27.4</p></td><td><p>76</p></td></tr></tbody></table><p>Source: NHS Digital, IAPT dataset</p><p>Notes:</p><p><sup>1</sup> NHS Bassetlaw CCG, NHS Mansfield and Ashfield CCG, NHS Newark and Sherwood CCG, NHS Nottingham City CCG, NHS Nottingham North and East CCG, NHS Nottingham West CCG and NHS Rushcliffe CCG.</p><p><sup>2</sup> Waiting time to enter treatment is calculated as the number of days between the referral received date and the first attended treatment appointment. Referral received date and the first treatment appointment dates do not necessarily occur in the same month.</p><p><sup>3</sup> In order to finish a course of treatment, a referral must have ended in the month with at least two treatment appointments having been attended in the course of the referral.</p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:13:47.043Zmore like thismore than 2019-07-25T16:13:47.043Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4663
unstar this property label Biography information for Ben Bradley more like this
1140903
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Eating Disorders: Mental Health Services more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when he will publish the adult commissioning guidance on adult eating disorder services. more like this
star this property tabling member constituency Westmorland and Lonsdale more like this
star this property tabling member printed
Tim Farron more like this
star this property uin 280277 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The NHS Mental Health Implementation Plan 2019/20 – 2023/24 published on 23 July 2019, states that publication of guidance on developing community-based services for adults with eating disorders is imminent.</p><p> </p><p>The guidance for commissioners and providers will aid the development of eating disorder services for adults and to inform sustainability and transformation plans for transforming community services for adults with eating disorders.</p><p> </p> more like this
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:08:19.26Zmore like thismore than 2019-07-25T16:08:19.26Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
1591
unstar this property label Biography information for Tim Farron more like this
1140913
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Maternal Mortality more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment he has made of the implications for his policies of the MBRRACE-UK maternal deaths and morbidity statistics 2014-16 showing that (a) Asian women are nearly twice as likely, (b) mixed race women are twice as likely and (c) black women are five times as likely to die during or up to six weeks after pregnancy than white women. more like this
star this property tabling member constituency Newport West more like this
star this property tabling member printed
Ruth Jones more like this
star this property uin 280405 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The NHS Long Term Plan takes a concerted and systematic approach to reducing health inequalities and addressing unwarranted variation in care. NHS England and NHS Improvement are leading the work through the Maternity Transformation Programme to support maternity services to provide high-quality maternity care for all women.</p><p>Targeted and enhanced continuity of carer can significantly improve outcomes for women from ethnic minorities. The NHS Long Term plan sets out that 75% of black women will receive continuity of carer from midwives by 2024.</p><p>The Department is also funding research to investigate the factors associated with the excess perinatal mortality experienced by black/black British and Asian/Asian British ethnic groups and identify the factors associated with the excess risk of maternal death for black and South Asian women.</p> more like this
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:19:04.357Zmore like thismore than 2019-07-25T16:19:04.357Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4716
unstar this property label Biography information for Ruth Jones more like this
1140957
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Metamizole: Side Effects more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what recent assessment has been made of the side-effects of the drug metamizole. more like this
star this property tabling member constituency Liverpool, Wavertree more like this
star this property tabling member printed
Luciana Berger more like this
star this property uin 280288 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN
280289 more like this
280290 more like this
star this property question first answered
less than 2019-07-25T16:07:40.7Zmore like thismore than 2019-07-25T16:07:40.7Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4036
unstar this property label Biography information for Luciana Berger more like this
1140958
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Metamizole: Spain more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, if he will have discussions with his Spanish counterpart on the effect of dispensing metamizole to (a) UK and (b) Spanish residents in Spain. more like this
star this property tabling member constituency Liverpool, Wavertree more like this
star this property tabling member printed
Luciana Berger more like this
star this property uin 280289 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN
280288 more like this
280290 more like this
star this property question first answered
less than 2019-07-25T16:07:40.76Zmore like thismore than 2019-07-25T16:07:40.76Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4036
unstar this property label Biography information for Luciana Berger more like this
1140960
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Metamizole: Spain more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what steps the Government is taking to raise awareness of the potential side-effects of the drug metamizole among UK citizens and tourists in Spain. more like this
star this property tabling member constituency Liverpool, Wavertree more like this
star this property tabling member printed
Luciana Berger more like this
star this property uin 280290 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>Metamizole is a medicine used in some European Union countries to treat severe pain and fever. Metamizole magnesium is authorised in Spain, Portugal and Poland (as a generic medicine and under various brand names including Nolotil in Spain and Portugal and Pyralgina in Poland). The medicine has not been licensed for use in the United Kingdom.</p><p>As with all medicines, the safety of metamizole is kept under close review within the EU. A European review was conducted last year to assess all data available concerning the maximum daily dose and its contraindications on pregnancy and breastfeeding. This review was completed in December 2018 and led to agreement of harmonised information on the maximum dose to be used and that it should not be used during the third trimester of pregnancy. It was also recommended that use during breast-feeding should be avoided. As a result, consistent warnings will be available in the product information for patients and healthcare professionals within each country where authorised for use.</p><p>A recent evaluation by the European Pharmacovigilance Risk Assessment Committee noted reports of cases of agranulocytosis (lowered white blood cell count) which had occurred in UK residents in Spain. Agranulocytosis is a known risk of metamizole and is described in the product information for healthcare professionals. However, based on the review of available data, the Spanish Medicines Agency has taken further action to strengthen the warnings with regards to the risk of agranulocytosis. We are also aware that in October 2018 a communication was issued to healthcare professionals in Spain reminding them of this risk and the need to advise patients of the signs and symptoms and to avoid use in patients who have risk factors for agranulocytosis.</p><p>All medicines are supplied with information for patients which contain information on all known side effects and those signs and symptoms which they need to be aware of. Patients being treated with metamizole medicines who have any questions or concerns should talk to a healthcare professional.</p><p> </p><p> </p><p><strong> </strong></p><p><strong> </strong></p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property grouped question UIN
280288 more like this
280289 more like this
star this property question first answered
less than 2019-07-25T16:07:40.807Zmore like thismore than 2019-07-25T16:07:40.807Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4036
unstar this property label Biography information for Luciana Berger more like this
1140972
unstar this property registered interest false more like this
star this property date remove filter
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Blood: Contamination more like this
star this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, what assessment has been made of the adequacy of palliative care arrangements and support in place for the victims of the contaminated blood scandal. more like this
star this property tabling member constituency Hornsey and Wood Green more like this
star this property tabling member printed
Catherine West more like this
star this property uin 280426 more like this
star this property answer
answer
star this property is ministerial correction false more like this
star this property date of answer less than 2019-07-25more like thismore than 2019-07-25
star this property answer text <p>The England Infected Blood Support Scheme (EIBSS) does not currently have direct support provisions for palliative care arrangements. EIBSS does however support beneficiaries to manage their health conditions via discretionary one-off payments.</p><p>Discretionary one-off payments are a form of financial support that beneficiaries and bereaved spouses/partners may apply for to cover the cost of certain essential, health-related items or services.</p><p>Some examples of the one-off payments we support are for home adaptations and repairs to support an individual’s medical conditions, assisting with respite breaks to aid recovery from periods of ill health and supporting the attendance of appointments by providing payments for car repairs and travel costs.</p><p>A full list of the items or services currently supported through EIBSS is available on the NHS Business Services Authority website at the following link:</p><p><a href="https://www.nhsbsa.nhs.uk/support-scheme-members/discretionary-support-scheme" target="_blank">https://www.nhsbsa.nhs.uk/support-scheme-members/discretionary-support-scheme</a></p>
star this property answering member constituency Thurrock more like this
star this property answering member printed Jackie Doyle-Price more like this
star this property question first answered
less than 2019-07-25T16:01:54.137Zmore like thismore than 2019-07-25T16:01:54.137Z
star this property answering member
4065
star this property label Biography information for Jackie Doyle-Price remove filter
star this property tabling member
4523
unstar this property label Biography information for Catherine West more like this